ArticleExperimental and therapeutic medicine2018
Leptin upregulates smooth muscle cell expression of MMP-9 to promote plaque destabilization by activating AP-1 via the leptin receptor/MAPK/ERK signaling pathways.
Article in Experimental and therapeutic medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- Evaluation of Human Stem Cell Conditioned Medium and Culture Conditions on Alleviating Elastase-Compromised Human Aortic Smooth Muscle Cell Function.Cardiovascular engineering and technology · 2026Article
- Review
- Adipose Tissue-Derived Adipokines in Vascular Physiology and Pathophysiology: Insights and Implications.Comprehensive Physiology · 2025Review
- Sarsasapogenin blocks ox-LDL-stimulated vascular smooth muscle cell proliferation, migration, and invasion through suppressing STIM1 expression.Cardiovascular diagnosis and therapy · 2023Article
- Regulation of cardiovascular health and disease by visceral adipose tissue-derived metabolic hormones.The Journal of physiology · 2023Article
- Fermented jellyfish (Frontiers in pharmacology · 2023Article
- Association of Matrix Metalloproteinase-2 (MMP-2) and MMP-9 Promoter Polymorphisms, Their Serum Levels, and Activities with Coronary Artery Calcification (CAC) in an Iranian Population.Cardiovascular toxicology · 2022Article
- Leptin in Atherosclerosis: Focus on Macrophages, Endothelial and Smooth Muscle Cells.International journal of molecular sciences · 2021Review
- Resolution of Deep Venous Thrombosis: Proposed Immune Paradigms.International journal of molecular sciences · 2020Review
- Adipose Tissue Immunomodulation: A Novel Therapeutic Approach in Cardiovascular and Metabolic Diseases.Frontiers in cardiovascular medicine · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leptin has been reported to be expressed in carotid atherosclerotic plaques, where it can promote lesion instability. Matrix metalloproteinases (MMPs) produced by smooth muscle cells (SMCs) are known to contribute to the weakening of atherosclerotic plaques via the degradation of extracellular matrix (ECM) proteins. The present study investigated whether leptin promotes plaque rupture by increasing the expression of MMP in SMCs
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.